Company Profile
Abeona Therapeutics Stock Price, News & Analysis
Company overview
Business overview
Abeona Therapeutics is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.
Geographic Base and Sector Classification
Headquartered in the United States and listed on NASDAQ, Abeona Therapeutics is followed within the biopharmaceutical universe for its exposure to pipeline and commercialization catalysts.
Business Model Characteristics
Abeona Therapeutics follows a pipeline-led model where clinical readouts, filing updates, and program expansion determine how the market underwrites the story.
Position Within the Biotechnology Landscape
Compared with more mature healthcare names, Abeona Therapeutics sits on the development side of the biotech landscape, where catalyst timing can reprice the stock quickly.
Why the stock is moving
ABEO is trading with a steady catalyst profile while investors wait for the next headline that changes the story.
Future catalysts
Abeona’s catalysts are prademagene zamikeracel and the epidermolysis-bullosa franchise, where regulatory and launch-readiness steps matter most. The market will care about whether the therapy can keep moving toward commercial reality.
Recent news
The five most recent feed items are shown below in reverse chronological order.
- 01
- 02
- 03
Abeona Therapeutics® Announces Permanent J-Code for ZEVASKYN® (prademagene zamikeracel)
Source: Abeona Therapeutics
- 04
- 05
Abeona Therapeutics® Reports Third Quarter 2025 Financial Results and Corporate Updates
Source: Abeona Therapeutics
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.